Abstract | AIMS: METHODS: In this multi-centre double-blind placebo controlled study, 60 patients with NYHA Class I-III heart failure were randomised to candoxatril 200 mg b.d. (n = 22), captopril 25-50 mg b.d. (n = 23) or placebo (n = 15). Treadmill exercise tests were carried out weekly during a 5-week single-blind placebo run-in phase until a stable baseline was achieved, and repeated at 4 weekly intervals during the 12-week double-blind treatment phase. RESULTS: Nine patients withdrew from the study--four candoxatril and five captopril. The placebo-adjusted increase in exercise duration after 12 weeks was 56 s (95% CI, -26 to +137 s; P = 0.12) with candoxatril and 37 s (-43 to + 117 s; P = 0.29) with captopril. CONCLUSIONS:
|
Authors | D B Northridge, P F Currie, D E Newby, J J McMurray, M Ford, N A Boon, H J Dargie |
Journal | European journal of heart failure
(Eur J Heart Fail)
Vol. 1
Issue 1
Pg. 67-72
(Mar 1999)
ISSN: 1388-9842 [Print] England |
PMID | 10937982
(Publication Type: Clinical Trial, Comparative Study, Journal Article, Multicenter Study, Randomized Controlled Trial)
|
Chemical References |
- Angiotensin-Converting Enzyme Inhibitors
- Indans
- Propionates
- Protease Inhibitors
- Captopril
- candoxatril
|
Topics |
- Angiotensin-Converting Enzyme Inhibitors
(pharmacology, therapeutic use)
- Captopril
(pharmacology, therapeutic use)
- Double-Blind Method
- Exercise Test
- Exercise Tolerance
(drug effects)
- Female
- Heart Failure
(drug therapy, physiopathology)
- Humans
- Indans
(pharmacology, therapeutic use)
- Male
- Middle Aged
- Propionates
(pharmacology, therapeutic use)
- Protease Inhibitors
(pharmacology, therapeutic use)
|